A Phase 3 interventional study of Benralizumab and Matching placebo in Eosinophilic Esophagitis, sponsored by AstraZeneca. Terminated at 78 sites in 12 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 165 studies in Eosinophilic Esophagitis with a site in United States — 23 open to participants now, 41 under way, 3 of them phase 3. Eosinophilic Esophagitis · United States.
Among the 165 studies in Eosinophilic Esophagitis with a site in United States, this one is the 11th largest by enrollment of the 111 interventional ones that give a count, is one of 11 that started in 2020, is one of 20 in phase 3, and was the 115th registered.
235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.
Browse Eosinophilic Esophagitis studies →23 of the 165 studies in Eosinophilic Esophagitis with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States, Mali
Ages 18–65
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–65
Johns Hopkins University · Sites in United States
Ages 5–21
Kate Farms Inc · Sites in United States
Ages 1–21
Medical College of Wisconsin · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.
This study: 12 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
165 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 38 · Phase 3 26 · Phase 4 10
First in 1996; this study’s year is marked. 11 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 211 is above the median of 42 across 134 interventional studies indexed under Eosinophilic Esophagitis.
Median enrollment 36 across the 111 interventional studies, 80 across the 53 observational. Of the 112 that completed or were terminated, 55 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 165 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 2 studies filed under Eosinophilic Esophagitis — fewer than ten, so there is no comparison to draw.
10 of the studies in Eosinophilic Esophagitis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06596252Phase 3Dr. Falk Pharma GmbHOnce Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE | 2026-12 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT03312686Indiana UniversityChanges in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study | 2026-12-31 |
| NCT02008903University of Colorado, DenverEsophageal String Test in Eosinophilic Esophagitis | 2027-01 |
| NCT06598462Uniquity One (UNI)A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis | 2027-04-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 165 studies in Eosinophilic Esophagitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this Phase 3 study is to investigate the use of benralizumab as a treatment for patients with EoE. The effect of doses of benralizumab on EoE histologic signs and symptoms will be assessed over a 52-week treatment period (including a 24-week double-blind placebo-controlled treatment period and a 28-week open-label treatment period). It is proposed that benralizumab will deplete eosinophils from GI tissue(s), improve the symptoms of dysphagia, and improve endoscopy scores as well as other markers of disease activity. Upon completion of the initial 52-week treatment period, patients will be offered an additional Open Label Extension period of at least 1 year, with benralizumab treatment and ongoing study assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must be symptomatic at Visit 1 (screening) and Visit 2 (randomization):
Exclusion Criteria:
Current active liver disease:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benralizumab active solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
Biological: Benralizumab
Placebo solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
Biological: Matching placebo
Solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC), 1 mL fill volume
Percentage of Patients With a Histologic Response, Defined as a Peak Esophageal Intraepithelial Eosinophil Count ≤ 6 Eos/Hpf.
Percentage of patients with a histologic response at Week 24 and Week 52. A histologic response is defined as a peak esophageal intraepithelial eosinophil count \<= 6 eos/hpf across all available esophageal levels. Subjects with no biopsy data at Week 24 or with intercurrent events prior to Week 24 such as changes to background medications or additional new therapies for EoE are considered non-responders. The number analyzed represents the number of participants in the treatment group that could have made it to the timepoint by the data cut off.
Time frame: Week 24, Week 52
Changes From Baseline in Dysphagia Symptom Questionnaire (DSQ)
The Dysphagia Symptom Questionnaire (DSQ) captures the presence and severity of dysphagia symptoms in the past day in a 4-item questionnaire. The DSQ score is calculated over 14-day periods and ranges from 0 to 84, with a lower score indicating less severe dysphagia. At least 8 days with evaluable daily score in 14-day period are required; otherwise the DSQ score for the period is set to missing. The number analyzed represents the number of participants with data at that visit (including patients with imputed values post intercurrent events).
Time frame: Week 24, Week 52
Percent Change From Baseline in Tissue Eosinophils
Percent change from baseline in tissue eosinophils (eos) at Week 24 and Week 52. The number analyzed represents the number of participants with data at that visit (including imputed values).
Time frame: Week 24, Week 52
Change From Baseline in Eosinophilic Esophagitis-Histology Scoring System (EoE-HSS) Total Grade Score at Week 24
EoE-HSS Grade and Stage Scores evaluate eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Total grade score (TGS): mean of the grade score ratios per region. Grade score ratio per region is the sum of all available feature grade scores divided by the maximum possible score. The maximum possible total grade score is 1. The number analyzed represents the number of participants with data at that visit (including imputed values).
Time frame: Week 24
Change From Baseline in Eosinophilic Esophagitis-Histology Scoring System (EoE-HSS) Total Stage Score at Week 24
EoE-HSS Grade and Stage Scores evaluate eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Total stage score (TSS): mean of the stage score ratios per region. Stage score ratio per region is the sum of all available feature stage scores divided by the maximum possible score. The maximum possible total stage score is 1. The number analyzed represents the number of participants with data at that visit (including imputed values).
Time frame: Week 24
Changes From Baseline in Centrally-read Endoscopic Reference Score (EREFS)
EREFS is a scoring system for assessing the presence and severity of the major endoscopic signs of EoE.The score ranges from 0 (normal) to 9 (severe disease). EREFS total score (TS): The worst score for each individual component from the proximal and distal scores were summed to form the EREFS total score (TS). The number analyzed represents the number of participants with data at that visit (including patients with imputed values post intercurrent events).
Time frame: Week 24, Week 52
Treatment Responder Rate at Week 24, Defined as a Composite of Histological Response (≤6eos/Hpf) and Clinically Meaningful Improvement From Baseline in Dysphagia Symptom Questionnaire (DSQ) (30% Improvement) at Week 24
Percentage of participants with a treatment response at Week 24. A treatment response is defined as composite of histologic response and clinically meaningful improvement (30% reduction) from baseline in DSQ score. Participants with missing data at Week 24 or with intercurrent events prior to Week 24 are considered non-responders.
Time frame: Week 24
Centrally-read Biopsies for Additional Histopathology Including Tissue Eosinophil Counts at Week 24
Esophagogastroduodenoscopy biopsies were collected at week 24 and sent to the central lab for slide preparation and for central, blinded pathology review of tissue eosinophil counts and histopathology. Centralized slide assessments and scoring from an independent physician review was performed for all biopsies.
Time frame: Week 24
Dysphagia-free Days as Captured by the Dysphagia Symptom Questionnaire (DSQ)
Dysphagia free days is a count ranging from 0-28. Higher counts indicate better outcomes. The number analyzed represents the number of participants with data at that visit.
Time frame: Week 24, Week 52
Frequency of Dysphagia Episodes as Captured by the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D)
EoE-3D is a daily diary focused on the patient experience of EoE. Dysphagia episode frequency is summarized as the total number of dysphagia episodes occurring over each 28-day period following randomization, scaled up to 28 days based on missing days. Requires at least 8 days of evaluable data in each 14-day period within each 28-day period; otherwise the period is set to missing. The number analyzed represents the number of participants with data at that visit.
Time frame: Week 24, Week 52
Changes From Baseline in Dysphagia Associated Pain, Discomfort, and Overall Severity as Captured by the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D) at Week 24
In the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D), patients report on whether they experienced episodes of difficulty swallowing in the past 24 hours and if so, how many. Patients respond to 3 questions on the pain, discomfort, and overall severity of the event using a numeric rating scale (0 \[no\] to 10 \[worst\]). This is repeated for each episode reported. Each category score is calculated as the sum of daily average values in the 14-day period divided by the number of days with available episodes of difficulty swallowing episodes during the same 14-day period (each of the three final scores range from 0 to 10, with higher values indicating a worse outcome in that category). Requires at least 8 days of evaluable data during the period; otherwise, the mean scores are set to missing. Days with 0 episodes of difficulty swallowing count as evaluable. In case all 14 days with 0 episode of difficulty swallowing, the score is set to missing.
Time frame: Week 24
Changes From Baseline in Dysphagia Associated Pain, Discomfort, and Overall Severity as Captured by the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D) at Week 52
In the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D), patients report on whether they experienced episodes of difficulty swallowing in the past 24 hours and if so, how many. Patients respond to 3 questions on the pain, discomfort, and overall severity of the event using a numeric rating scale (0 \[no\] to 10 \[worst\]). This is repeated for each episode reported. Each category score is calculated as the sum of daily average values in the 14-day period divided by the number of days with available episodes of difficulty swallowing episodes during the same 14-day period (each of the three final scores range from 0 to 10, with higher values indicating a worse outcome in that category). Requires at least 8 days of evaluable data during the period; otherwise, the mean scores are set to missing. Days with 0 episodes of difficulty swallowing count as evaluable. In case all 14 days with 0 episode of difficulty swallowing, the score is set to missing.
Time frame: Week 52
Changes From Baseline in Abdominal Pain and Nausea as Captured by the Daily Diary at Week 24
In the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D), respondents are asked to report the severity of abdominal pain and the severity of nausea at their worst over the past 24 hours using an 11-point numeric rating scale (0 \[no\] to 10 \[worst\]). Abdominal pain severity and nausea severity will be summarized individually as 14-day mean scores. Each 14-day mean score will be calculated as the sum of daily numerical rating scale score responses divided by the number of days with evaluable data in the same 14-day period. Calculation of the 14-day means will require at least 8 out of 14 days of evaluable data; otherwise, the mean score will be set to missing. The number analyzed represents the number of participants with data at that visit (including participants with imputed values post intercurrent events).
Time frame: Week 24
Changes From Baseline in Abdominal Pain and Nausea as Captured by the Daily Diary at Week 52
In the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D), respondents are asked to report the severity of abdominal pain and the severity of nausea at their worst over the past 24 hours using an 11-point numeric rating scale (0 \[no\] to 10 \[worst\]). Abdominal pain severity and nausea severity will be summarized individually as 14-day mean scores. Each 14-day mean score will be calculated as the sum of daily numerical rating scale score responses divided by the number of days with evaluable data in the same 14-day period. Calculation of the 14-day means will require at least 8 out of 14 days of evaluable data; otherwise, the mean score will be set to missing. The number analyzed represents the number of participants with data at that visit (including participants with imputed values post intercurrent events).
Time frame: Week 52
Changes From Baseline in the Pediatric Eosinophilic Esophagitis Symptom Severity Module (PEESS)
The Pediatric Eosinophilic Esophagitis Symptom Severity Module, Version 2, Children and Teens Report (PEESS) is an 18-item assessment of EoE symptom severity and frequency validated for use in patients age 8 to 18 years. The recall period is one month. The first 18 questions alternate between a question about a given symptom's frequency (never=0, almost never=1, sometimes=2, often=3, almost always=4) and a question about the symptom's severity (face rating scale with drawings representing: not bad at all=0, a little bad=1, kind of bad=2, bad=3, very bad=4). The remaining two questions ask about frequency of eating less food than others and frequency of needing more time to eat than others. The overall score ranges from 0 to 80, with higher scores representing more severe and frequent EoE symptoms. The number analyzed represents the number of participants with data at that visit.
Time frame: Week 24, Week 52
Changes From Baseline in Adult Eosinophilic Esophagitis Quality of Life Questionnaire (EOE-QoL-A) at Week 24
The Adult Eosinophilic Esophagitis Quality of Life Questionnaire (EoE-QoL-A) is a 30-item assessment developed specifically to measure health-related quality of life in patients with EoE. Responses are on a 5-point scale: Not at all = 4, Slightly = 3, Moderately = 2, Quite a Bit = 1, Extremely = 0. The assessment has 5 domains: eating/diet impact, social impact, emotional impact, disease anxiety and swallowing anxiety. Domain scores are calculated as follows: * Eating/Diet Impact (range 0 to 40): sum of Q2, Q9, Q16, Q24, Q25, Q26, Q27, Q28, Q29, Q30 * Social Impact (range 0 to 16): sum of Q14, Q17, Q19, Q22 * Emotional Impact (range 0 to 32): sum of Q1, Q5, Q6, Q7, Q11, Q13, Q21, Q23 * Disease Anxiety (range 0 to 20): sum of Q4, Q10, Q12, Q15, Q18, * Swallowing Anxiety (range 0 to 12): sum of Q3, Q8, Q20 The total score (range 0 to 120) is calculated as the sum of all responses. Lower scores indicate a greater degree of impairment. Higher scores indicate a better quality of life.
Time frame: Week 24
Changes From Baseline in Adult Eosinophilic Esophagitis Quality of Life Questionnaire (EOE-QoL-A) at Week 52
The Adult Eosinophilic Esophagitis Quality of Life Questionnaire (EoE-QoL-A) is a 30-item assessment developed specifically to measure health-related quality of life in patients with EoE. Responses are on a 5-point scale: Not at all = 4, Slightly = 3, Moderately = 2, Quite a Bit = 1, Extremely = 0. The assessment has 5 domains: eating/diet impact, social impact, emotional impact, disease anxiety and swallowing anxiety. Domain scores are calculated as follows: * Eating/Diet Impact (range 0 to 40): sum of Q2, Q9, Q16, Q24, Q25, Q26, Q27, Q28, Q29, Q30 * Social Impact (range 0 to 16): sum of Q14, Q17, Q19, Q22 * Emotional Impact (range 0 to 32): sum of Q1, Q5, Q6, Q7, Q11, Q13, Q21, Q23 * Disease Anxiety (range 0 to 20): sum of Q4, Q10, Q12, Q15, Q18, * Swallowing Anxiety (range 0 to 12): sum of Q3, Q8, Q20 The total score (range 0 to 120) is calculated as the sum of all responses. Lower scores indicate a greater degree of impairment. Higher scores indicate a better quality of life.
Time frame: Week 52
Change From Baseline in Short Form 36-item Health Survey (Version 2, Acute Recall) (SF-36v2) at Week 24
The Short Form 36-item Health Survey, version 2, acute recall (SF-36v2) is a 36-item, self-report survey of functional health and well-being, with a 1-week recall period. There are 8 domain scores: Physical Functioning (PF), Role Limitations due to Physical Health (RP), Bodily Pain (BP), General Health Perceptions (GH), Vitality (VT), Social Functioning (SF), Role Limitations due to Emotional Problems (RE), and Mental Health (MH). Psychometrically-based physical and mental health component summary scores (PCS and MCS, respectively) were computed from subscale scores to give a broader metric of physical and mental health-related quality of life. All scores range from 0-100, with higher scores meaning better outcomes. The number analyzed represents the number of participants with data at that visit (including participants with imputed values post intercurrent events).
Time frame: Week 24
Change From Baseline in Short Form 36-item Health Survey (Version 2, Acute Recall) (SF-36v2) at Week 52
The Short Form 36-item Health Survey, version 2, acute recall (SF-36v2) is a 36-item, self-report survey of functional health and well-being, with a 1-week recall period. There are 8 domain scores: Physical Functioning (PF), Role Limitations due to Physical Health (RP), Bodily Pain (BP), General Health Perceptions (GH), Vitality (VT), Social Functioning (SF), Role Limitations due to Emotional Problems (RE), and Mental Health (MH). Psychometrically-based physical and mental health component summary scores (PCS and MCS, respectively) were computed from subscale scores to give a broader metric of physical and mental health-related quality of life. All scores range from 0-100, with higher scores meaning better outcomes. The number analyzed represents the number of participants with data at that visit (including participants with imputed values post intercurrent events).
Time frame: Week 52
Percent of Patients With Relevant Concomitant Procedures and Healthcare Resource Utilization at Week 24 and Week 52.
Percent of patients with any relevant concomitant procedures or healthcare resource utilization for Eosinophilic esophagitis (EoE) or an EoE-related episode (e.g., an intervention for food impaction or stricture requiring dilatation) since last healthcare resource utilization assessment during the previous scheduled visit. Assessed at Week 24 and Week 52.
Time frame: Week 24, Week 52
Patient Reported Overall Severity of Disease as Measured by Patient Global Impression of Severity (PGI-S) at Week 24
Patient Global Impression of Severity (PGI-S) is an assessment of the patient's perceived disease severity. The answer options are "no symptoms," "very mild," "mild," "moderate," "severe," and "very severe." The number analyzed represents the participants with evaluable PGI-S results at that timepoint.
Time frame: Week 24
Patient Reported Overall Severity of Disease as Measured by Patient Global Impression of Severity (PGI-S) at Week 52
Patient Global Impression of Severity (PGI-S) is an assessment of the patient's perceived disease severity. The answer options are "no symptoms," "very mild," "mild," "moderate," "severe," and "very severe." The number analyzed represents the participants with evaluable PGI-S results at that timepoint.
Time frame: Week 52
Patient Reported Change in Health Status Since Baseline as Measured by Patient Global Impression of Change (PGI-C) at Week 24
Patient Global Impression of Change (PGI-C) measures the patient's overall impression of response to treatment since the initial dose. The answer options are "much better," "moderately better," "a little better," "about the same/no change," "a little worse," "moderately worse," and "much worse." The number analyzed represents the participants with evaluable PGI-C results at that timepoint.
Time frame: Week 24
Patient Reported Change in Health Status Since Baseline as Measured by Patient Global Impression of Change (PGI-C) at Week 52
Patient Global Impression of Change (PGI-C) measures the patient's overall impression of response to treatment since the initial dose. The answer options are "much better," "moderately better," "a little better," "about the same/no change," "a little worse," "moderately worse," and "much worse." The number analyzed represents the participants with evaluable PGI-C results at that timepoint.
Time frame: Week 52
Benralizumab Pharmacokinetics
Serum concentrations of benralizumab through Week 52. Geometric mean calculated using log transformed data.
Time frame: Up to week 52
Immunogenicity of Benralizumab in Double Blind Period
Immunogenicity of benralizumab assessed by ADA and nAb in the Double Blind period.
Time frame: Up to Week 24
Immunogenicity of Benralizumab in Double Blind + Open Label Periods
Immunogenicity of benralizumab assessed by ADA and nAb in the Double Blind and Open Label periods.
Time frame: Up to Week 52
Safety and Tolerability in Double Blind Period
Percentage of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Double Blind treatment period (up to Week 24).
Time frame: Up to Week 24
Safety and Tolerability in the Open Label Period
Percentage of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Open Label treatment period (past week 24).
Time frame: From Week 24 up to Week 52
A total of 404 participants were screened between 22SEP2020 and 22FEB2022. Of those, 211 were randomized to either the treatment (104 participants) or placebo (107 participants) arms of the double-blind treatment period. One participant, who did not meet inclusion/exclusion criteria, was incorrectly randomized but not dosed. Therefore, 103 participants started in the treatment arm and 107 in the placebo arm, for a total of 210 participants.
| Milestone | Benralizumab | Placebo |
|---|---|---|
| Started | 103 | 107 |
| Completed | 101 | 106 |
| Not completed | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Subject perceives the ip to be ineffective. | 1 | 0 |
| Milestone | Benralizumab | Placebo |
|---|---|---|
| Started | 100 | 105 |
| Completed | 79 | 82 |
| Not completed | 21 | 23 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Study terminated by sponsor | 17 | 19 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Milestone | Benralizumab | Placebo |
|---|---|---|
| Started | 45 | 48 |
| Completed | 0 | 0 |
| Not completed | 45 | 48 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Study terminated by sponsor | 44 | 44 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Unable to schedule gastroscopy | 0 | 1 |
| Withdrew: No study/treatment discontinuation information | 0 | 1 |
Percentage of patients with a histologic response at Week 24 and Week 52. A histologic response is defined as a peak esophageal intraepithelial eosinophil count \<= 6 eos/hpf across all available esophageal levels. Subjects with no biopsy data at Week 24 or with intercurrent events prior to Week 24 such as changes to background medications or additional new therapies for EoE are considered non-responders. The number analyzed represents the number of participants in the treatment group that could have made it to the timepoint by the data cut off.
| Percentage of Participants | Benralizumab | Placebo |
|---|---|---|
| Week 24 | 87.4 (80.97 to 93.79) | 6.5 (1.86 to 11.23) |
| Week 52 | 82.6 (71.66 to 93.56) | 89.4 (80.55 to 98.18) |
The Dysphagia Symptom Questionnaire (DSQ) captures the presence and severity of dysphagia symptoms in the past day in a 4-item questionnaire. The DSQ score is calculated over 14-day periods and ranges from 0 to 84, with a lower score indicating less severe dysphagia. At least 8 days with evaluable daily score in 14-day period are required; otherwise the DSQ score for the period is set to missing. The number analyzed represents the number of participants with data at that visit (including patients with imputed values post intercurrent events).
| Score | Benralizumab | Placebo |
|---|---|---|
| Week 24 | -12.102 (-16.05 to -8.15) | -15.101 (-19.02 to -11.19) |
| Week 52 | -19.409 (-25.65 to -13.17) | -19.806 (-25.70 to -13.91) |
Percent change from baseline in tissue eosinophils (eos) at Week 24 and Week 52. The number analyzed represents the number of participants with data at that visit (including imputed values).
| Percentage of change | Benralizumab | Placebo |
|---|---|---|
| Week 24 | -94.8 (-100.00 to -82.45) | 1.4 (-11.75 to 14.60) |
| Week 52 | -85.0 (-100.00 to -62.50) | -88.6 (-100.00 to -73.67) |
EoE-HSS Grade and Stage Scores evaluate eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Total grade score (TGS): mean of the grade score ratios per region. Grade score ratio per region is the sum of all available feature grade scores divided by the maximum possible score. The maximum possible total grade score is 1. The number analyzed represents the number of participants with data at that visit (including imputed values).
| Grade Score Ratio Change | Benralizumab | Placebo |
|---|---|---|
| Change From Baseline in Eosinophilic Esophagitis-Histology Scoring System (EoE-HSS) Total Grade Score at Week 24 | -0.264 (-0.297 to -0.232) | -0.089 (-0.122 to -0.056) |
EoE-HSS Grade and Stage Scores evaluate eight features: eosinophil density, basal zone hyperplasia, eosinophil abscesses, eosinophil surface layering, dilated intercellular spaces, surface epithelial alteration, dyskeratotic epithelial cells, and lamina propria fibrosis. Severity (grade) and extent (stage) of abnormalities will be scored using a 4-point scale (0 normal; 3 maximum change). Total stage score (TSS): mean of the stage score ratios per region. Stage score ratio per region is the sum of all available feature stage scores divided by the maximum possible score. The maximum possible total stage score is 1. The number analyzed represents the number of participants with data at that visit (including imputed values).
| Grade Score Ratio Change | Benralizumab | Placebo |
|---|---|---|
| Change From Baseline in Eosinophilic Esophagitis-Histology Scoring System (EoE-HSS) Total Stage Score at Week 24 | -0.199 (-0.228 to -0.169) | -0.077 (-0.107 to -0.046) |
EREFS is a scoring system for assessing the presence and severity of the major endoscopic signs of EoE.The score ranges from 0 (normal) to 9 (severe disease). EREFS total score (TS): The worst score for each individual component from the proximal and distal scores were summed to form the EREFS total score (TS). The number analyzed represents the number of participants with data at that visit (including patients with imputed values post intercurrent events).
| Score | Benralizumab | Placebo |
|---|---|---|
| Week 24 | -0.5 (-0.91 to -0.10) | -0.4 (-0.85 to -0.01) |
| Week 52 | -0.3 (-0.9 to 0.32) | -0.7 (-1.35 to -0.09) |
Percentage of participants with a treatment response at Week 24. A treatment response is defined as composite of histologic response and clinically meaningful improvement (30% reduction) from baseline in DSQ score. Participants with missing data at Week 24 or with intercurrent events prior to Week 24 are considered non-responders.
| Percentage of Participants | Benralizumab | Placebo |
|---|---|---|
| Treatment Responder Rate at Week 24, Defined as a Composite of Histological Response (≤6eos/Hpf) and Clinically Meaningful Improvement From Baseline in Dysphagia Symptom Questionnaire (DSQ) (30% Improvement) at Week 24 | 43.7 (34.11 to 53.27) | 4.7 (0.67 to 8.67) |
Esophagogastroduodenoscopy biopsies were collected at week 24 and sent to the central lab for slide preparation and for central, blinded pathology review of tissue eosinophil counts and histopathology. Centralized slide assessments and scoring from an independent physician review was performed for all biopsies.
| Participants | Benralizumab | Placebo |
|---|---|---|
| <1 eos/hpf | 84 | 0 |
| 1 to <=6 eos/hpf | 6 | 7 |
| 7 to <15 eos/hpf | 2 | 3 |
| 15 to <60 eos/hpf | 0 | 33 |
| >=60 eos/hpf | 2 | 56 |
Dysphagia free days is a count ranging from 0-28. Higher counts indicate better outcomes. The number analyzed represents the number of participants with data at that visit.
| Days | Benralizumab | Placebo |
|---|---|---|
| Week 24 | 12.65 ± 10.589 | 16.32 ± 11.286 |
| Week 52 | 19.33 ± 10.950 | 20.80 ± 10.472 |
EoE-3D is a daily diary focused on the patient experience of EoE. Dysphagia episode frequency is summarized as the total number of dysphagia episodes occurring over each 28-day period following randomization, scaled up to 28 days based on missing days. Requires at least 8 days of evaluable data in each 14-day period within each 28-day period; otherwise the period is set to missing. The number analyzed represents the number of participants with data at that visit.
| Ratio of Episodes per 28 Day period | Benralizumab | Placebo |
|---|---|---|
| Week 24 | 20.3 ± 28.05 | 13.8 ± 19.15 |
| Week 52 | 6.8 ± 11.59 | 6.2 ± 9.83 |
In the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D), patients report on whether they experienced episodes of difficulty swallowing in the past 24 hours and if so, how many. Patients respond to 3 questions on the pain, discomfort, and overall severity of the event using a numeric rating scale (0 \[no\] to 10 \[worst\]). This is repeated for each episode reported. Each category score is calculated as the sum of daily average values in the 14-day period divided by the number of days with available episodes of difficulty swallowing episodes during the same 14-day period (each of the three final scores range from 0 to 10, with higher values indicating a worse outcome in that category). Requires at least 8 days of evaluable data during the period; otherwise, the mean scores are set to missing. Days with 0 episodes of difficulty swallowing count as evaluable. In case all 14 days with 0 episode of difficulty swallowing, the score is set to missing.
| Scores per day | Benralizumab | Placebo |
|---|---|---|
| Dysphagia-related pain | -0.452 (-0.86 to -0.05) | -0.412 (-0.84 to 0.02) |
| Dysphagia-related discomfort | -0.370 (-0.73 to -0.01) | -0.189 (-0.57 to 0.19) |
| Overall episode severity | -0.481 (-0.83 to -0.13) | -0.137 (-0.51 to 0.24) |
In the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D), patients report on whether they experienced episodes of difficulty swallowing in the past 24 hours and if so, how many. Patients respond to 3 questions on the pain, discomfort, and overall severity of the event using a numeric rating scale (0 \[no\] to 10 \[worst\]). This is repeated for each episode reported. Each category score is calculated as the sum of daily average values in the 14-day period divided by the number of days with available episodes of difficulty swallowing episodes during the same 14-day period (each of the three final scores range from 0 to 10, with higher values indicating a worse outcome in that category). Requires at least 8 days of evaluable data during the period; otherwise, the mean scores are set to missing. Days with 0 episodes of difficulty swallowing count as evaluable. In case all 14 days with 0 episode of difficulty swallowing, the score is set to missing.
| Scores per day | Benralizumab | Placebo |
|---|---|---|
| Dysphagia-related pain | -0.511 (-1.40 to 0.38) | -0.776 (-1.65 to 0.10) |
| Dysphagia-related discomfort | -0.456 (-1.14 to 0.22) | -0.625 (-1.30 to 0.05) |
| Overall episode severity | -0.522 (-1.26 to 0.22) | -0.732 (-1.48 to 0.02) |
In the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D), respondents are asked to report the severity of abdominal pain and the severity of nausea at their worst over the past 24 hours using an 11-point numeric rating scale (0 \[no\] to 10 \[worst\]). Abdominal pain severity and nausea severity will be summarized individually as 14-day mean scores. Each 14-day mean score will be calculated as the sum of daily numerical rating scale score responses divided by the number of days with evaluable data in the same 14-day period. Calculation of the 14-day means will require at least 8 out of 14 days of evaluable data; otherwise, the mean score will be set to missing. The number analyzed represents the number of participants with data at that visit (including participants with imputed values post intercurrent events).
| Scores per day | Benralizumab | Placebo |
|---|---|---|
| Abdominal pain severity | -0.549 (-0.94 to -0.16) | -0.815 (-1.20 to -0.53) |
| Nausea severity | -0.524 (-0.90 to -0.15) | -0.820 (-1.19 to -0.45) |
In the Eosinophilic Esophagitis Daily Dysphagia Diary (EoE-3D), respondents are asked to report the severity of abdominal pain and the severity of nausea at their worst over the past 24 hours using an 11-point numeric rating scale (0 \[no\] to 10 \[worst\]). Abdominal pain severity and nausea severity will be summarized individually as 14-day mean scores. Each 14-day mean score will be calculated as the sum of daily numerical rating scale score responses divided by the number of days with evaluable data in the same 14-day period. Calculation of the 14-day means will require at least 8 out of 14 days of evaluable data; otherwise, the mean score will be set to missing. The number analyzed represents the number of participants with data at that visit (including participants with imputed values post intercurrent events).
| Scores per day | Benralizumab | Placebo |
|---|---|---|
| Abdominal pain severity | -0.826 (-1.44 to -0.22) | -1.039 (-1.62 to -0.46) |
| Nausea severity | -0.855 (-1.43 to -0.28) | -0.960 (-1.50 to -0.42) |
The Pediatric Eosinophilic Esophagitis Symptom Severity Module, Version 2, Children and Teens Report (PEESS) is an 18-item assessment of EoE symptom severity and frequency validated for use in patients age 8 to 18 years. The recall period is one month. The first 18 questions alternate between a question about a given symptom's frequency (never=0, almost never=1, sometimes=2, often=3, almost always=4) and a question about the symptom's severity (face rating scale with drawings representing: not bad at all=0, a little bad=1, kind of bad=2, bad=3, very bad=4). The remaining two questions ask about frequency of eating less food than others and frequency of needing more time to eat than others. The overall score ranges from 0 to 80, with higher scores representing more severe and frequent EoE symptoms. The number analyzed represents the number of participants with data at that visit.
| Score | Benralizumab | Placebo |
|---|---|---|
| Week 24 | -0.8 ± 11.69 | -5.9 ± 14.24 |
| Week 52 | -6.5 ± 18.04 | -12.5 ± 15.67 |
The Adult Eosinophilic Esophagitis Quality of Life Questionnaire (EoE-QoL-A) is a 30-item assessment developed specifically to measure health-related quality of life in patients with EoE. Responses are on a 5-point scale: Not at all = 4, Slightly = 3, Moderately = 2, Quite a Bit = 1, Extremely = 0. The assessment has 5 domains: eating/diet impact, social impact, emotional impact, disease anxiety and swallowing anxiety. Domain scores are calculated as follows: * Eating/Diet Impact (range 0 to 40): sum of Q2, Q9, Q16, Q24, Q25, Q26, Q27, Q28, Q29, Q30 * Social Impact (range 0 to 16): sum of Q14, Q17, Q19, Q22 * Emotional Impact (range 0 to 32): sum of Q1, Q5, Q6, Q7, Q11, Q13, Q21, Q23 * Disease Anxiety (range 0 to 20): sum of Q4, Q10, Q12, Q15, Q18, * Swallowing Anxiety (range 0 to 12): sum of Q3, Q8, Q20 The total score (range 0 to 120) is calculated as the sum of all responses. Lower scores indicate a greater degree of impairment. Higher scores indicate a better quality of life.
| Score | Benralizumab | Placebo |
|---|---|---|
| Eating/Diet Impact | 1.370 (-0.27 to 3.01) | 1.169 (-0.46 to 2.79) |
| Social Impact | 1.095 (0.21 to 1.98) | 0.948 (0.07 to 1.83) |
| Emotional Impact | 0.912 (-0.46 to 2.29) | 0.902 (-0.46 to 2.27) |
| Disease Anxiety | 0.185 (-0.77 to 1.14) | -0.201 (-1.15 to 0.75) |
| Swallowing Anxiety | 0.443 (-0.23 to 1.12) | 0.605 (-0.06 to 1.27) |
| Total Score | 4.380 (-0.36 to 9.12) | 3.362 (-1.33 to 8.06) |
The Adult Eosinophilic Esophagitis Quality of Life Questionnaire (EoE-QoL-A) is a 30-item assessment developed specifically to measure health-related quality of life in patients with EoE. Responses are on a 5-point scale: Not at all = 4, Slightly = 3, Moderately = 2, Quite a Bit = 1, Extremely = 0. The assessment has 5 domains: eating/diet impact, social impact, emotional impact, disease anxiety and swallowing anxiety. Domain scores are calculated as follows: * Eating/Diet Impact (range 0 to 40): sum of Q2, Q9, Q16, Q24, Q25, Q26, Q27, Q28, Q29, Q30 * Social Impact (range 0 to 16): sum of Q14, Q17, Q19, Q22 * Emotional Impact (range 0 to 32): sum of Q1, Q5, Q6, Q7, Q11, Q13, Q21, Q23 * Disease Anxiety (range 0 to 20): sum of Q4, Q10, Q12, Q15, Q18, * Swallowing Anxiety (range 0 to 12): sum of Q3, Q8, Q20 The total score (range 0 to 120) is calculated as the sum of all responses. Lower scores indicate a greater degree of impairment. Higher scores indicate a better quality of life.
| Score | Benralizumab | Placebo |
|---|---|---|
| Eating/Diet Impact | 1.408 (-1.01 to 3.83) | 1.949 (-0.32 to 4.21) |
| Social Impact | 1.462 (0.09 to 2.83) | 1.984 (0.70 to 3.27) |
| Emotional Impact | 1.768 (-0.21 to 3.75) | 2.451 (0.58 to 4.33) |
| Disease Anxiety | 1.063 (-0.43 to 2.56) | 1.152 (-0.27 to 2.57) |
| Swallowing Anxiety | 0.677 (-0.37 to 1.72) | 1.085 (0.10 to 2.07) |
| Total Score | 6.749 (-0.35 to 13.84) | 8.714 (2.03 to 15.40) |
The Short Form 36-item Health Survey, version 2, acute recall (SF-36v2) is a 36-item, self-report survey of functional health and well-being, with a 1-week recall period. There are 8 domain scores: Physical Functioning (PF), Role Limitations due to Physical Health (RP), Bodily Pain (BP), General Health Perceptions (GH), Vitality (VT), Social Functioning (SF), Role Limitations due to Emotional Problems (RE), and Mental Health (MH). Psychometrically-based physical and mental health component summary scores (PCS and MCS, respectively) were computed from subscale scores to give a broader metric of physical and mental health-related quality of life. All scores range from 0-100, with higher scores meaning better outcomes. The number analyzed represents the number of participants with data at that visit (including participants with imputed values post intercurrent events).
| Score | Benralizumab | Placebo |
|---|---|---|
| Physical functioning (PF) | 0.2 (-1.36 to 1.70) | 0.5 (-0.98 to 1.97) |
| Role limitations due to physical health (RP) | 0.5 (-1.03 to 2.10) | 1.5 (-0.06 to 2.99) |
| Bodily pain (BP) | -0.6 (-2.92 to 1.82) | 0.2 (-2.07 to 2.53) |
| General health perceptions (GH) | -0.9 (-2.62 to 0.78) | -0.9 (-2.54 to 0.76) |
| Vitality (VT) | -0.5 (-2.47 to 1.54) | -0.5 (-2.50 to 1.48) |
| Social functioning (SF) | -1.5 (-3.84 to 0.92) | 0.1 (-2.26 to 2.39) |
| Role limitations due to emotional problems (RE) | -1.1 (-3.68 to 1.51) | -0.4 (-2.95 to 2.15) |
| Mental health (MH) | -1.7 (-3.83 to 0.51) | -0.8 (-2.91 to 1.31) |
| Psychometrically-based physical summary score (PCS) | 0.4 (-1.21 to 2.01) | 0.8 (-0.75 to 2.34) |
| Mental health component summary scores (MCS) | -1.8 (-4.10 to 0.53) | -1.2 (-3.44 to 1.11) |
The Short Form 36-item Health Survey, version 2, acute recall (SF-36v2) is a 36-item, self-report survey of functional health and well-being, with a 1-week recall period. There are 8 domain scores: Physical Functioning (PF), Role Limitations due to Physical Health (RP), Bodily Pain (BP), General Health Perceptions (GH), Vitality (VT), Social Functioning (SF), Role Limitations due to Emotional Problems (RE), and Mental Health (MH). Psychometrically-based physical and mental health component summary scores (PCS and MCS, respectively) were computed from subscale scores to give a broader metric of physical and mental health-related quality of life. All scores range from 0-100, with higher scores meaning better outcomes. The number analyzed represents the number of participants with data at that visit (including participants with imputed values post intercurrent events).
| Score | Benralizumab | Placebo |
|---|---|---|
| Physical functioning (PF) | 0.3 (-1.86 to 2.51) | 0.4 (-1.60 to 2.46) |
| Role limitations due to physical health (RP) | -0.5 (-3.27 to 2.20) | 0.9 (-1.63 to 3.51) |
| Bodily pain (BP) | 0.6 (-2.69 to 3.97) | 1.8 (-1.34 to 5.00) |
| General health perceptions (GH) | 2.3 (-0.71 to 5.39) | 0.7 (-2.17 to 3.59) |
| Vitality (VT) | -0.2 (-2.69 to 2.31) | -2.0 (-4.42 to 0.44) |
| Social functioning (SF) | 0.2 (-3.73 to 4.17) | -0.5 (-4.26 to 3.34) |
| Role limitations due to emotional problems (RE) | -0.1 (-3.30 to 3.19) | -0.3 (-3.39 to 2.76) |
| Mental health (MH) | 1.2 (-1.37 to 3.69) | -1.1 (-3.46 to 1.30) |
| Psychometrically-based physical summary score (PCS) | 0.5 (-2.15 to 3.18) | 1.4 (-1.15 to 3.85) |
| Mental health component summary scores (MCS) | 0.5 (-2.44 to 3.50) | -1.9 (-4.78 to 0.89) |
Percent of patients with any relevant concomitant procedures or healthcare resource utilization for Eosinophilic esophagitis (EoE) or an EoE-related episode (e.g., an intervention for food impaction or stricture requiring dilatation) since last healthcare resource utilization assessment during the previous scheduled visit. Assessed at Week 24 and Week 52.
| Participants | Benralizumab | Placebo |
|---|---|---|
| Week 24 | 3 | 5 |
| Week 52 | 0 | 2 |
Patient Global Impression of Severity (PGI-S) is an assessment of the patient's perceived disease severity. The answer options are "no symptoms," "very mild," "mild," "moderate," "severe," and "very severe." The number analyzed represents the participants with evaluable PGI-S results at that timepoint.
| Participants | Benralizumab | Placebo |
|---|---|---|
| No symptoms | 4 | 11 |
| Very mild | 23 | 27 |
| Mild | 34 | 32 |
| Moderate | 29 | 17 |
| Severe | 3 | 6 |
| Very Severe | 3 | 2 |
Patient Global Impression of Severity (PGI-S) is an assessment of the patient's perceived disease severity. The answer options are "no symptoms," "very mild," "mild," "moderate," "severe," and "very severe." The number analyzed represents the participants with evaluable PGI-S results at that timepoint.
| Participants | Benralizumab | Placebo |
|---|---|---|
| No symptoms | 6 | 10 |
| Very mild | 12 | 14 |
| Mild | 9 | 13 |
| Moderate | 8 | 5 |
| Severe | 0 | 0 |
| Very Severe | 1 | 0 |
Patient Global Impression of Change (PGI-C) measures the patient's overall impression of response to treatment since the initial dose. The answer options are "much better," "moderately better," "a little better," "about the same/no change," "a little worse," "moderately worse," and "much worse." The number analyzed represents the participants with evaluable PGI-C results at that timepoint.
| Participants | Benralizumab | Placebo |
|---|---|---|
| Much better | 13 | 13 |
| Moderately better | 13 | 17 |
| A little better | 21 | 20 |
| About the same | 37 | 36 |
| A little worse | 7 | 6 |
| Moderately worse | 3 | 3 |
| Much worse | 2 | 1 |
Patient Global Impression of Change (PGI-C) measures the patient's overall impression of response to treatment since the initial dose. The answer options are "much better," "moderately better," "a little better," "about the same/no change," "a little worse," "moderately worse," and "much worse." The number analyzed represents the participants with evaluable PGI-C results at that timepoint.
| Participants | Benralizumab | Placebo |
|---|---|---|
| Much better | 12 | 13 |
| Moderately better | 3 | 12 |
| A little better | 8 | 12 |
| About the same | 9 | 6 |
| A little worse | 4 | 0 |
| Moderately worse | 0 | 0 |
| Much worse | 0 | 0 |
Serum concentrations of benralizumab through Week 52. Geometric mean calculated using log transformed data.
| ng/mL | Benralizumab | Placebo |
|---|---|---|
| Week 8 | 1555.70 (1425.31 to 1698.02) | — |
| Week 16 | 1582.46 (1322.66 to 1893.30) | — |
| Week 24 | 1338.65 (1027.05 to 1744.78) | NA (NA to NA) |
| Week 36 | 1405.94 (985.94 to 2004.86) | 1362.27 (1051.69 to 1764.58) |
| Week 52 | 1278.13 (749.19 to 2180.52) | 1495.61 (975.73 to 2292.50) |
Immunogenicity of benralizumab assessed by ADA and nAb in the Double Blind period.
| Participants | Benralizumab | Placebo |
|---|---|---|
| ADA positive/ADA prevalence (positive at baseline and/or post-baseline) | 18 | 8 |
| ADA negative (negative at all assessments) | 85 | 99 |
| Treatment-emergent ADA positive/ADA incidence | 18 | 4 |
| ADA persistently positive | 18 | 3 |
| ADA positive subjects with maximum titre > median of maximum titres | 6 | 4 |
| nAb positive/nAb prevalence | 10 | 0 |
| ADA persistently positive and nAb positive | 10 | 0 |
Immunogenicity of benralizumab assessed by ADA and nAb in the Double Blind and Open Label periods.
| Participants | Benralizumab | Placebo |
|---|---|---|
| ADA positive/ADA prevalence (positive at baseline and/or post-baseline) | 19 | 17 |
| ADA negative (negative at all assessments) | 84 | 88 |
| Treatment-emergent ADA positive/ADA incidence | 19 | 11 |
| ADA persistently positive | 16 | 10 |
| ADA positive subjects with maximum titre > median of maximum titres | 7 | 7 |
| nAb positive/nAb prevalence | 10 | 5 |
| ADA persistently positive and nAb positive | 10 | 5 |
Percentage of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Double Blind treatment period (up to Week 24).
| Participants | Benralizumab | Placebo |
|---|---|---|
| Any AE | 66 | 66 |
| Any SAE | 2 | 1 |
Percentage of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Open Label treatment period (past week 24).
| Participants | Benralizumab | Placebo |
|---|---|---|
| Any AE | 53 | 60 |
| Any SAE | 2 | 4 |
Collected over On study AEs were collected from the first dose to the last date in study, up to 104 weeks.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benra 30 mg | 0/103 (0%) | 4/103 (3.9%) | 60/103 (58.3%) |
| Placebo | 0/107 (0%) | 1/107 (0.9%) | 42/107 (39.3%) |
| All Benra | 0/208 (0%) | 9/208 (4.3%) | 95/208 (45.7%) |
| Event | Benra 30 mg | Placebo | All Benra |
|---|---|---|---|
| Oesophageal food impactionGastrointestinal disorders | 1/103 | 0/107 | 3/208 |
| Infectious pleural effusionInfections and infestations | 1/103 | 0/107 | 1/208 |
| Pneumonia bacterialInfections and infestations | 1/103 | 0/107 | 1/208 |
| Affective disorderPsychiatric disorders | 1/103 | 0/107 | 1/208 |
| DepressionPsychiatric disorders | 1/103 | 0/107 | 1/208 |
| Disruptive mood dysregulation disorderPsychiatric disorders | 1/103 | 0/107 | 1/208 |
| Oppositional defiant disorderPsychiatric disorders | 1/103 | 0/107 | 1/208 |
| Suicide attemptPsychiatric disorders | 1/103 | 0/107 | 1/208 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 1/103 | 0/107 | 1/208 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/103 | 1/107 | 0/208 |
| Event | Benra 30 mg | Placebo | All Benra |
|---|---|---|---|
| COVID-19Infections and infestations | 34/103 | 13/107 | 49/208 |
| NasopharyngitisInfections and infestations | 12/103 | 6/107 | 19/208 |
| HeadacheNervous system disorders | 12/103 | 11/107 | 14/208 |
| DiarrhoeaGastrointestinal disorders | 7/103 | 3/107 | 11/208 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 6/103 | 1/107 | 7/208 |
| PharyngitisInfections and infestations | 5/103 | 0/107 | 5/208 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 5/103 | 4/107 | 9/208 |
| Injection site erythemaGeneral disorders | 5/103 | 2/107 | 7/208 |
| Upper respiratory tract infectionInfections and infestations | 4/103 | 5/107 | 8/208 |
| Back painMusculoskeletal and connective tissue disorders | 4/103 | 0/107 | 6/208 |
All participants who were randomized and received any IP were included in the full analysis set.
| Age, Continuous(years) | Benralizumab | Placebo | Total |
|---|---|---|---|
| Mean | 33.9 ± 13.49 | 33.6 ± 12.73 | 33.7 ± 13.08 |
| Age, Customized(Participants) | Benralizumab | Placebo | Total |
|---|---|---|---|
| < 18 years old | 14 | 14 | 28 |
| 18-21 years old | 11 | 11 | 22 |
| 22-35 years old | 32 | 35 | 67 |
| >= 36 years old | 46 | 47 | 93 |
| Age, Customized(Participants) | Benralizumab | Placebo | Total |
|---|---|---|---|
| <= 21 years old | 25 | 25 | 50 |
| > 21 years old | 78 | 82 | 160 |
| Sex: Female, Male(Participants) | Benralizumab | Placebo | Total |
|---|---|---|---|
| Female | 31 | 22 | 53 |
| Male | 72 | 85 | 157 |
| Race/Ethnicity, Customized(Participants) | Benralizumab | Placebo | Total |
|---|---|---|---|
| Black or African American | 1 | 1 | 2 |
| White | 97 | 96 | 193 |
| Native Hawaiian or other Pacific Islander | 0 | 1 | 1 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 5 | 7 |
| Other | 3 | 1 | 4 |
| Race/Ethnicity, Customized(Participants) | Benralizumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 10 | 16 |
| Non-Hispanic or Latino | 97 | 94 | 191 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Sep 2020 to primary completion in Sep 2022, 23 months.
Results were first posted in Nov 2023, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab